Camilla Petrycer Hansen, non-executive director representing Novo Holdings

Camilla Petrycer Hansen currently serves as a principal at Novo Holdings, where she focuses on company creation and early-stage investments. She is also part of the investment team in the REPAIR Impact Fund. She is a member of the Board of Directors of Hoba Therapeutics and Centauri Therapeutics and also acts as an observer on the Boards of Directors for Muna and Hemab. Camilla previously worked in various business development roles spanning positions at early-stage to commercial-stage companies (e.g., Novozymes, Statens Serum Institute (SSI) and Wake Forest University Health Sciences in the United States). She holds a PhD in Medicinal Chemistry and a Master of Pharmacy from Copenhagen University.